Alexander Luft

9.8k total citations · 3 hit papers
21 papers, 1.7k citations indexed

About

Alexander Luft is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Alexander Luft has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Alexander Luft's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Alexander Luft is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Alexander Luft collaborates with scholars based in United States, Germany and Russia. Alexander Luft's co-authors include Igor Bondarenko, Martin Reck, Raju Titus Chacko, Piotr Serwatowski, Thomas J. Lynch, Fabrice Barlési, Haolan Lu, Jean-Marie Cuillerot, Martin Sebastian and Joel W. Neal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Alexander Luft

21 papers receiving 1.7k citations

Hit Papers

Ipilimumab in Combination With Paclitaxel and Carboplatin... 2012 2026 2016 2021 2012 2016 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    2012 816 citations Thomas J. Lynch, Igor Bondarenko et al. Journal of Clinical Oncology profile →
  2. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
  3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander Luft United States 8 1.5k 705 492 282 274 21 1.7k
Raju Titus Chacko India 9 1.3k 0.9× 508 0.7× 587 1.2× 302 1.1× 224 0.8× 38 1.6k
Alexander Luft Russia 16 2.0k 1.4× 1.0k 1.5× 362 0.7× 398 1.4× 560 2.0× 35 2.3k
Hidenobu Ishii Japan 15 1.0k 0.7× 692 1.0× 185 0.4× 166 0.6× 179 0.7× 55 1.3k
Caicun Zhou China 25 1.4k 1.0× 1.3k 1.8× 259 0.5× 389 1.4× 97 0.4× 39 2.0k
Ahad A. Sadiq United States 9 1.3k 0.9× 1.0k 1.4× 223 0.5× 204 0.7× 62 0.2× 17 1.6k
Yien Ning Sophia Wong United Kingdom 8 687 0.5× 350 0.5× 325 0.7× 387 1.4× 103 0.4× 17 1.1k
Mikhail Dvorkin United States 13 746 0.5× 487 0.7× 153 0.3× 127 0.5× 137 0.5× 43 924
Satoru Kitazono Japan 23 1.0k 0.7× 833 1.2× 108 0.2× 349 1.2× 125 0.5× 92 1.5k
Etienne Giroux‐Leprieur France 23 1.0k 0.7× 706 1.0× 194 0.4× 492 1.7× 64 0.2× 77 1.5k
Hirva Mamdani United States 19 597 0.4× 436 0.6× 143 0.3× 364 1.3× 115 0.4× 102 1.0k

Countries citing papers authored by Alexander Luft

Since Specialization
Citations

This map shows the geographic impact of Alexander Luft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Luft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Luft more than expected).

Fields of papers citing papers by Alexander Luft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Luft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Luft. The network helps show where Alexander Luft may publish in the future.

Co-authorship network of co-authors of Alexander Luft

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Luft. A scholar is included among the top collaborators of Alexander Luft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Luft. Alexander Luft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peters, Solange, Byoung Chul Cho, Alexander Luft, et al.. (2023). LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study. Immuno-Oncology Technology. 20. 100693–100693. 2 indexed citations
2.
Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2022). 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Annals of Oncology. 33. S29–S30. 2 indexed citations
3.
Garon, Edward B., Byoung Chul Cho, Niels Reinmuth, et al.. (2021). Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer. 22(4). 301–312.e8. 20 indexed citations
4.
Kim, Hye Ryun, Mark M. Awad, Alejandro Navarro, et al.. (2020). 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC. Annals of Oncology. 31. S1033–S1034. 4 indexed citations
5.
Reck, Martin, Alexander Luft, Igor Bondarenko, et al.. (2019). A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC. Annals of Oncology. 30. v644–v645. 2 indexed citations
6.
7.
Garon, Edward B., Byoung Chul Cho, Niels Reinmuth, et al.. (2019). Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology. 37(15_suppl). 9048–9048. 1 indexed citations
8.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2018). Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Annals of Oncology. 29. viii748–viii749. 2 indexed citations
9.
10.
Ajani, Jaffer A., Anghel Adrian Udrea, Tomasz Sarosiek, et al.. (2017). A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. Annals of Oncology. 28. v238–v238. 3 indexed citations
11.
12.
Ciuleanu, Tudor–Eliade, Mark A. Socinski, Coleman K. Obasaju, et al.. (2017). Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 19(2). 130–138.e2. 15 indexed citations
13.
Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →
14.
Thatcher, Nick, Fred R. Hirsch, Alexander Luft, et al.. (2015). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. The Lancet Oncology. 16(7). 763–774. 331 indexed citations breakdown →
15.
Socinski, Mark A., Alexander Luft, Aleksandra Szczęsna, et al.. (2015). Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). e19023–e19023. 2 indexed citations
16.
Reck, Martin, Mark A. Socinski, Alexander Luft, et al.. (2014). Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study. Annals of Oncology. 25. iv445–iv445. 1 indexed citations
17.
Edelman, Martin J., Claus-Peter Schneider, Chun‐Ming Tsai, et al.. (2013). Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status. Journal of Clinical Oncology. 31(16). 1990–1996. 24 indexed citations
18.
Lynch, Thomas J., Igor Bondarenko, Alexander Luft, et al.. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. Journal of Clinical Oncology. 30(17). 2046–2054. 816 indexed citations breakdown →
19.
Lynch, Thomas J., Igor Bondarenko, Alexander Luft, et al.. (2010). Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7531–7531. 41 indexed citations
20.
Ready, Neal, С. В. Орлов, Alexander Luft, et al.. (2009). AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. Journal of Clinical Oncology. 27(15_suppl). 3577–3577. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raju Titus Chacko Breakdown of academic impact, for papers by Alexander Luft Breakdown of academic impact, for papers by Hidenobu Ishii Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Ahad A. Sadiq Breakdown of academic impact, for papers by Yien Ning Sophia Wong Breakdown of academic impact, for papers by Mikhail Dvorkin Breakdown of academic impact, for papers by Satoru Kitazono Breakdown of academic impact, for papers by Etienne Giroux‐Leprieur Breakdown of academic impact, for papers by Hirva Mamdani
Rankless by CCL
2026